Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 15/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 8/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410180 | 0.89 | FDPS (0.37) | FDPSLMNAGGPS1LPAR1LPAR3 | |
| SCHEMBL3357002 | 0.85 | FDPS (0.50) | FDPSGGPS1LPAR1LPAR3SMPD1 | |
| SCHEMBL2942969 | 0.70 | ALDH1A1 (0.32) | — | |
| SCHEMBL8718782 | 0.69 | GGPS1 (0.50) | FDPSLMNAGGPS1LPAR1LPAR3 | |
| SCHEMBL6296955 | 0.69 | FDPS (0.43) | FDPSLMNAGGPS1LPAR1LPAR3 | |
| SCHEMBL246809 | 0.69 | FDPS (0.43) | FDPSLMNAGGPS1LPAR1LPAR3 | |
| SCHEMBL1768259 | 0.69 | FDPS (0.43) | FDPSLMNAGGPS1LPAR1LPAR3 | |
| SCHEMBL8522272 | 0.69 | LAP3 (0.41) | FDPSLMNAGGPS1 | |
| SCHEMBL1227298 | 0.67 | FDPS (0.33) | FDPSLPAR3 | |
| SCHEMBL2342024 | 0.67 | FDPS (0.37) | FDPSLMNAGGPS1LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851429-B2 | AMPK activators | KALLYOPE, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-20220227754-A1 | AMPK ACTIVATORS | KALLYOPE, INC. | 2022-07-21 | — | — | US | disclosed |
| US-7470724-B2 | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20060035866-A1 | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES, INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035866-A1 | Phosphonate compounds having immuno-modulatory activity | PHOSPHO1, NFATC1, IFNG | FDPS 363/4885LMNA 4759/4885GGPS1 179/4885 |
| US-20220227754-A1 | AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAG3 | FDPS 1809/4885LMNA 3464/4885GGPS1 1933/4885 |
| US-11851429-B2 | AMPK activators | PRKAG1, PRKAG2, PRKAG3 | FDPS 1809/4885LMNA 3464/4885GGPS1 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.